Bragar Eagel & Squire, P.C. Is Investigating Oak Street Health, Hollysys Automation, and Cronos Group and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Oak Street Health, Inc. (NYSE: OSH), Hollysys Automation Technologies Ltd. (NASDAQ: HOLI), and Cronos Group, Inc. (NASDAQ: CRON). Our investigations concern whether these companies have violated the federal securities laws andor engaged in other unlawful business practices. Additional information about each case can be found at the link provided.

Oak Street Health, Inc. (NYSE: OSH)

In Oak Street's Q3 update on Monday, November 8, 2021, the Company revealed that the U.S. Department of Justice (DOJ) is investigating whether it may have violated the False Claims Act and said the DOJ has requested documents and information related to Oak Street providing free transportation to federal healthcare beneficiaries and related to its relationships with third-party marketing agents.

On this news, Oak Street's stock price fell $9.75 per share, or 20%, to close at $37.14 on November 9, 2021, thereby injuring investors.

For more information on the Oak Street Health investigation go to: https://bespc.com/cases/OSH

Hollysys Automation Technologies Ltd. (NASDAQ: HOLI)

On November 2, 2021, Hollysys filed a notice with the U.S. Securities and Exchange Commission stating that the Company could not timely file its annual report for the period ended June 30, 2021 because of a "delay in collecting supporting documents and information." Hollysys also disclosed that it had replaced Ernst & Young Hua Ming LLP as its independent auditor.

On this news, Hollysys's stock price fell $5.69 per share, or 29%, to close at $13.70 per share on November 3, 2021.

For more information on the Hollysys Automation investigation go to: https://bespc.com/cases/HOLI

Cronos Group, Inc. (NASDAQ: CRON)

On November 9, 2021, Cronos filed a Form 8-K with the U.S. Securities and Exchange Commission, stating that "[o]n November 8, 2021, Cronos Group Inc. . . . determined that it will be required to restate its previously issued unaudited interim financial statements for the three and six months ended June 30, 2021 previously filed on Form 10-Q on August 6, 2021" and advising that "[t]he Company's financial statements for this period should therefore no longer be relied upon." Cronos further stated that "[t]he Company concluded that it should have recorded an impairment charge of not less than $220 million on goodwill and indefinite-lived intangible assets in its U.S. reporting unit for the three and six months ended June 30, 2021. The Company will restate its unaudited interim financial statements for the three and six months ended June 30, 2021, accordingly." According to Cronos, the Company "is also evaluating whether to record an additional impairment in the three and nine months ended September 30, 2021."

On this news, Cronos's stock price fell $1.01 per share, or 15.05%, to close at $5.70 per share on November 9, 2021.

For more information on the Cronos Group investigation go to: https://bespc.com/cases/CRON

About Bragar Eagel & Squire, P.C.:

Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, California, and South Carolina. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com . Attorney advertising. Prior results do not guarantee similar outcomes.

Contact Information:

Bragar Eagel & Squire, P.C.
Brandon Walker, Esq.
Alexandra B. Raymond, Esq.
(212) 355-4648
investigations@bespc.com
www.bespc.com


Primary Logo

News Provided by GlobeNewswire via QuoteMedia

CRON:CA,CRON
The Conversation (0)
Cannabis leaf.

10 Biggest Cannabis Stocks in the US and Canada

2024 saw the cannabis industry grappling with persistent challenges, mirroring those of the preceding two years. The absence of meaningful regulatory reform in both the US and Canada continues to stifle market growth

There was some positive momentum in the US as new markets entered the industry and the US Drug Enforcement Administration moved to reschedule cannabis from Schedule I to Schedule III; however, subsequent roadblocks suggest the process could take longer than industry hopefuls originally anticipated.

Cannabis companies in the sector continue to move forward and develop their offerings, and with potential catalysts ahead some investors are interested in getting involved. Looking at the key players is often a good place to get started, so this list of US and Canadian cannabis stocks covers the companies with the largest presence in two major cannabis ETFs.

This list of the biggest publicly traded cannabis companies was put together based on the top-weighted cannabis stocks included in the AdvisorShares Pure US Cannabis ETF (ARCA:MSOS) and the Horizons Marijuana Life Sciences Index ETF (TSX:HMMJ) as of December 23, 2024. Share price information for the companies was accurate as of that time.

Keep reading...Show less
Cannabis plant under fluorescent light.

Cannabis Market Forecast: Top Trends for Cannabis in 2025

2025 could be a year of transformation for the cannabis industry.

With rescheduling potentially on the horizon in the US, a new era of opportunity awaits. However, with a new president set to take the helm in January, uncertainty and key challenges remain for market participants.

Read on to learn more about trends that could shape the cannabis market in what may be a critical year.

Keep reading...Show less
Cannabis business with marijuana leaves and stock

Cannabis Market 2024 Year-End Review

Cannabis is becoming increasingly mainstream in North America.

Recent Pew Research Center analysis reveals that most Americans now live in states where recreational cannabis is legal, and a remarkable 79 percent have at least one dispensary in their county.

However, federal legalization remains elusive, creating questions for investors watching the space.

Keep reading...Show less

Trulieve to Open Medical Cannabis Dispensary in Columbus, Georgia

New Muscogee County location will host grand opening celebration Friday, December 20 th

Trulieve Cannabis Corp. (CSE: TRUL ) (OTCQX: TCNNF )  ("Trulieve" or "the Company"), a leading and top-performing cannabis company in the United States today announced the opening of a new medical cannabis dispensary in Columbus, Georgia .

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less

Trulieve to Open Medical Cannabis Dispensary in Tampa, Florida

New Hillsborough County location will host grand opening celebration Friday December 13

Trulieve Cannabis Corp. (CSE: TRUL ) (OTCQX: TCNNF ) ("Trulieve" or "the Company"), a leading and top-performing cannabis company in the U.S., today announced the opening of a new medical cannabis dispensary in Tampa, Florida .

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less
Cannabis leaves, US flag.

Cannabis Round-Up: DEA Postpones Rescheduling Hearing, Key Players Share Quarterly Results

November was a busy month for the cannabis industry, with a slew of US-centric developments.

A hearing on cannabis rescheduling was postponed until 2025, although the incoming Trump administration has signaled its intent to follow through on the change despite opposition from some Republican lawmakers.

Meanwhile, several states voted on cannabis measures, and companies reported their latest quarterly results.

Keep reading...Show less

Latest Press Releases

Related News

×